The study indicates a significant advancement in neuroblastoma treatment, showcasing the potential of existing drugs in enhancing cancer therapies.
The dual action of TETA not only targets the tumor directly but also boosts the immune system, which is crucial in fighting cancer effectively.
The research underscores the importance of drug repurposing in oncology, potentially leading to faster and more cost-effective treatment options.
If further clinical trials confirm these findings, TETA could become a standard part of neuroblastoma treatment protocols, significantly improving outcomes for affected children.
The success of TETA may encourage more research into the repurposing of existing drugs for other types of cancers, potentially leading to breakthroughs in treatment strategies.
A new study from the University of New South Wales reveals that the existing drug TETA (triethylenetetramine) can significantly improve treatment for high-risk neuroblastoma in children. This rare cancer, which primarily affects children under five, can potentially see survival rates increase from 10% to 50% with the addition of TETA to current immunotherapy treatments.
The drug works by transporting copper to immune cells, enhancing the immune response while simultaneously weakening tumors. Lead researcher Associate Professor Orazio Vittorio emphasized the dual effect of TETA, stating that it strengthens the immune system's ability to combat the disease.
Dr. Jordyn Rowan, the study's lead author, highlighted the non-toxic nature of TETA, which has shown no significant side effects, making it a promising option for improving the quality of life for children battling this aggressive cancer. Additionally, repurposing TETA accelerates the treatment process and reduces costs compared to developing new drugs, which can take over a decade.
